Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...
Asianet Newsable on MSN16h
New antibody reduces tumor growth in tough-to-treat breast and ovarian cancers: StudyImmunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...
Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...
Immunotherapy, or antibody treatment that activates the patient’s own immune system against cancer, is increasingly being ...
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Ciara Foskin’s diagnosis came out of the blue. She is part of a small cohort of women under 50 who develop triple-negative ...
Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...
Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback